Latest From CollPlant Ltd.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in November and December 2016.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Medtronic's INFUSE bone morphogenetic protein is the only product in the musculoskeletal industry that has changed the bar in terms of bone healing, and it is under fire for complications related to off-label use. As regulators and payors crack down on INFUSE and hospitals restrict access to the product, surgeons are seeking alternatives and there are a number of companies lining up to fill the void
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- Middle East
- Parent & Subsidiaries
- CollPlant Ltd.
- Senior Management
Yehiel Tal, CEO
Eran Rotem, CFO
Nadav Orr, PhD, VP, R&D
Revital Mandil-Levin, PhD, Chief Bus. Dev. Officer
Oded Shoseyov, PhD, CSO
- Contact Info
Phone: (972) 73-232-5600
Weizmann Science Park
3 Sapir St.
P.O. Box 4132 Ness Ziona, 74140
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.